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Abstract
Systemic sclerosis (SSc) is a complex, multiorgan, autoimmune
disease. Lung fibrosis occurs inz80% of patients with SSc; 25%
to 30% develop progressive interstitial lung disease (ILD). The
pathogenesis of fibrosis in SSc-associated ILD (SSc-ILD) involves
cellular injury, activation/differentiation of mesenchymal cells, and
morphological/biological changes in epithelial/endothelial cells.
Risk factors for progressive SSc-ILD include older age, male sex,
degree of lung involvement on baseline high-resolution computed
tomography imaging, reduced DLCO, and reduced FVC. SSc-ILD
does not share the genetic risk architecture observed in idiopathic
pulmonary fibrosis (IPF), with key risk factors yet to be identified.
Presence of anti–Scl-70 antibodies and absence of anti-centromere
antibodies indicate increased likelihood of progressive ILD.
Elevated levels of serum Krebs von den Lungen-6 and C-reactive
protein are both associated with SSc-ILD severity and predict
SSc-ILD progression. A promising prognostic indicator is serum
chemokine (C-C motif) ligand 18. SSc-ILD shares similarities
with IPF, although clear differences exist. Histologically, a
nonspecific interstitial pneumonia pattern is commonly
observed in SSc-ILD, whereas IPF is defined by usual interstitial
pneumonia. The course of SSc-ILD is variable, ranging from
minor, stable disease to a progressive course, whereas all patients
with IPF experience progression of disease. Although
appropriately treated patients with SSc-ILD have better chances
of stabilization and survival, a relentlessly progressive course,
akin to IPF, is seen in a minority. Better understanding of cellular
andmolecular pathogenesis, genetic risk, and distinctive features
of SSc-ILD and identification of robust prognostic biomarkers
are needed for optimal disease management.
Keywords: systemic sclerosis; interstitial lung diseases;
autoimmune diseases; risk factors; biomarkers
Systemic sclerosis (SSc) is a complex
autoimmune disease with a range of
manifestations, including vasculopathy,
Raynaud’s phenomenon, immune
dysfunction, and fibrosis of the skin and
internal organs (1–3). It is a rare disease,
with an estimated global prevalence of 3 to
24 per 100,000 (4). Diagnostic criteria for
SSc were published jointly by the European
League against Rheumatism and the
American College of Rheumatology in
2013, with a scoring system based on a
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range of possible signs, symptoms, and
autoantibodies (5).
Lung fibrosis occurs in up to
approximately 80% of patients with SSc,
with varying prevalence depending on
ascertainment methods, and 25% to 30% of
patients develop progressive interstitial lung
disease (ILD) (2). In a large international
cohort study, 35% of SSc-related deaths
were attributed to pulmonary fibrosis,
making it the leading cause of mortality in
this patient population (6). The course of
SSc-associated ILD (SSc-ILD) is highly
variable; some patients have limited or
stable lung involvement, whereas in others,
lung disease progresses inexorably. Because
of the largely irreversible and potentially
progressive nature of ILD, it is important
that diagnostic tests are performed early, so
that treatment can be initiated with
minimal delay.
In this article, we review SSc-ILD with a
focus on pathogenesis, risk factors, and
patient characteristics associated with the
condition, with a view to identifying patients
most at risk for the disease and its
progression. We also highlight similarities
and differences between SSc-ILD and
idiopathic pulmonary fibrosis (IPF), the
most frequent and deadly of the idiopathic
ILDs.
Pathogenesis
The architectural disruption and collagen-
rich extracellular matrix (ECM) in SSc-ILD
results from the interaction of cells in the
epithelial, endothelial, and interstitial
compartments with components of the
innate and adaptive immune system and the
ECM, after chronic microinjuries in the
lung. The first step in the pathological
process is believed to comprise repetitive
endothelial and epithelial cell injury. This
leads to activation of the innate and adaptive
immune system, recruitment and activation
of fibroblasts, and differentiation of
fibroblasts to a myofibroblast phenotype (7),
with accumulation of ECM and
development of fibrosis (8). Apoptosis is
triggered in some epithelial cells, and others
undergo epithelial–mesenchymal transition
(7). Many of the phenotypic changes
occurring in respiratory epithelial cells in
the context of fibrosis remain unknown and
require further study. Cells undergoing
epithelial–mesenchymal transition exhibit
profound morphological and biological
changes, such as loss of polarity, increased
capacity for migration, increased
production of ECM components, and
increased resistance to apoptosis (7).
Resistance to apoptosis is also characteristic
of certain myofibroblasts, which may
contribute to the rate and extent of fibrosis
(7) in SSc-ILD.
A plausible model of pathogenesis
for parenchymal lung involvement in
connective tissue disease, which
consolidates current evidence on SSc-ILD
pathology and describes initial alveolar
epithelial and endothelial injuries that are
triggered by environmental factors,
pathogens, or inflammation, is shown in
Figure 1 (9). The latter event results in
damage to the lung tissue and initiation of
repair pathways including the recruitment
of fibroblasts and myofibroblasts; close
anatomical and functional interactions
between alveolar epithelial and endothelial
compartments result in recruitment of
circulating cellular components and
mediators, such as platelets and progenitor
cells. In this model, myofibroblasts are key
profibrotic cells that persist in affected lung
tissue; the extent of their persistence
determines the pattern and type of fibrotic
reaction. Interplay of myofibroblasts with
the ECM via matricellular proteins, such as
integrins and microfibrils, together with
soluble factors, such as connective tissue
growth factor, drive the fibrotic process.
The degree of irreversible architectural
disruption likely determines the
progression or reversibility of the lung
condition (9).
TGF-b (transforming growth factor-b)
is believed to be one of the key factors in
the process of fibrosis. It has been
implicated in ECM accumulation and the
regulation of immune response (7, 8).
Injured cells secrete TGF-b, which leads to
the recruitment of immune cells, including
macrophages, which in turn release more
TGF-b (7). Increased expression of genes
regulated by TGF-b has been confirmed in
patients with progressive lung fibrosis (10).
Type 2 helper T cells that secrete IL
(e.g., IL-4 and IL-13) are also believed to
play a role in the development of fibrosis
(8). Moreover, levels of thrombin are
increased in the lungs of patients with
SSc-ILD (7), probably as a consequence of
cellular injury. In addition to its role in
the coagulation cascade, thrombin may
contribute to fibrosis by increasing
proliferation of fibroblasts in response to
fibrinogen and facilitating differentiation
of fibroblasts into myofibroblasts (7).
The Wnt/b-catenin pathway has been
implicated in the activation of fibroblasts
and in pulmonary tissue remodeling (7).
Elements involved in the pathogenesis
of SSc, such as IL-6 and M2-like
macrophages, may also contribute to the
development of SSc-ILD, especially early
in the disease (11–13). Increases in
macrophage polarization, elevated C-
reactive protein, and serum IL-6 levels have
been associated with the progression of
early SSc-ILD (10, 12, 14).
Genetics and Epigenetics
SSc-ILD has been associated with a number
of HLA-dependent genes and non-HLA
genes (see Tables E1 and E2 in the online
supplement) (15). After the analyses of at
least 200 patients with SSc-ILD, only two
variants conferred an odds ratio of at least
2.0 with statistical significance: HLA-
DRB1*3 (Han Chinese population) and
CTGF rs6918698 (GG genotype; UK
population) (15).
Despite the number of reported
associations, genetic biomarkers relevant to
the risk of ILD in patients with SSc are yet to
be established with certainty (15). Many of
the individual studies reporting associations
of genetic variants with SSc-ILD have been
small, and follow-up studies of specific
associations are either lacking or have
reported conflicting data. Therefore, a
concerted effort is needed, involving large
numbers of patients of different ethnicities,
to establish more definite genetic risk
factors for SSc-ILD and its progression.
A few studies have investigated the
epigenetics of SSc-ILD (7). Epigenetic
factors that may play a role in the
pathogenesis of SSc-ILD include CpG
methylation, which is related to increased
DNA methyltransferase expression
in fibroblasts. Increased DNA
methyltransferase expression may affect the
activities of nitric oxide synthase or the
collagen transcription suppression factor
Fli1 (Friend leukemia virus integration 1).
Fli1 appears to play a role in protecting
against ILD, by upregulating the expression
of genes, including autoimmune regulator
and CXCL13 (7, 16). A genome-wide study
of genes in peripheral blood mononuclear
cells identified four methylation-regulated
genes (F2R, FYN, PAG1, and PRKCH) as
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being underexpressed in patients with SSc-
ILD versus patients with SSc and no ILD
(17). Significantly increased expression of
the XRCC4 DNA repair gene was reported
in patients with SSc with versus without
ILD (18). Micro-RNA (miRNA) expression
has also been assessed in animal models
and in lung tissue and peripheral blood
mononuclear cells derived from patients
with SSc-ILD. Studies have shown that
increased expression of miR-155 is
associated with worsened lung function
and increased lung fibrosis (19).
Risk Factors for the
Development and
Progression of SSc-ILD
Risk factors associated with progressive ILD
among patients with SSc include diffuse
cutaneous SSc, male sex, African
American race, and the presence of
anti–Scl-70 antibodies, also known as
antitopoisomerase I antibodies or ATA,
discussed previously in the section on
genetics and epigenetics (20–22). Other
indices of SSc-ILD severity have also been
associated with progressive disease,
including the extent of disease on high-
resolution computed tomography (HRCT)
imaging, reduced DLCO (% predicted), and
decreased FVC (% predicted) (23, 24).
Similarly, risk factors for mortality in
SSc-ILD include older age, male sex, extent
of disease on HRCT imaging, lower FVC,
and lower DLCO (23). Several models,
including the Composite Physiologic Index;
Interstitial Lung Disease–Gender, Age,
Physiology Index; du Bois index; and
modified du Bois index, have been reported
to help predict mortality in patients with
SSc-ILD (25). These models are based on
readily available clinical details, such as age,
sex, and FVC. HRCT imaging is routinely
performed at most centers, and the findings
can be integrated with pulmonary function
test results as per the Limited/Extensive
Staging System developed by Goh and
colleagues for SSc-ILD (26). This staging
system, which is based on the visual
estimation of extent of disease on HRCT
and, as necessary, integrated with FVC
(% predicted), appears to predict the
patient’s risk of mortality more accurately
than either of the component variables
when used in isolation (26). This validated
staging system proposes the rapid
identification of limited or extensive lung
disease using HRCT on the basis of a
disease extent threshold of 20%. In cases in
which disease extent remains indeterminate
on HRCT, FVC is used to classify lung
disease as either limited or extensive on the
basis of an FVC threshold of 70%. This
system represents a practical means of
integrating HRCT extent and functional
severity in routine prognostic evaluation
(26). HRCT images from patients with SSc-
ILD are provided in Figures 2, 3, and 4 to
demonstrate examples of ILD with limited,
indeterminate, and extensive disease on
CT imaging, according to the Goh and
colleagues 20% threshold (26). Stratification
of patients using this system has been
shown to be predictive of both progression-
free survival and mortality.
The 6-minute-walk test has also been
demonstrated to be an independent
predictor of mortality in SSc-ILD. Certain
blood biomarkers may also be used to
predict the risk of disease progression
(27, 28), although they are not routinely
used in clinical practice.
In the SLS (Scleroderma Lung Study) I
(NCT00004563) and II (NCT00883129),
higher baseline skin score, older age, and a
Collagen
matrix
•
•
2. Progression
Proliferation of diverse
fibroblasts*
•
•
•
•
•
Fibrocyte recruitment
EMT
Ongoing epithelial/endothelial
damage
Increased numbers of diverse
myofibroblasts (derived from
fibroblasts, pericytes,
endothelial cells, and 
monocytes)
Increased activity of
myofibroblasts
Monocyte–macrophage cross
talk
Myofibroblast
Interstitial
fibroblast
MyofibroblastPericyteFibrocyte
Collagen
Endothelial cell injury and apoptosis Endothelial cell
Interstitial
fibroblast*
Antibody
lgG
Cytokines
Type ll pneumocyte
NK Cell
Collagen matrix–myofibroblast
drives/sustains
myofibroblast activity
Epithelial cells
undergoing EMT
Matricellular protein
3. Failed resolution
Myofibroblast persistence•
•
•
•
Altered matricellular interaction
Perturbed repair
Ongoing demage
1. Endothelial/epithelial injury
Endothelial/epithelial damage
Endothelial activation
Immune-cell infiltration
Inflammation
•
•
•
•
Myofibroblast Monocyte
Alveolar macrophage Neutrophil T cell
EosinophilType l pneumocyte
B Cell
Epithelial cell
damage
and apoptosis
Figure 1. Cellular pathogenesis of fibrotic lung injury in systemic sclerosis. *Including SPINT2hi, MFAP5hi, and few WIF1hi fibroblasts. EMT= epithelial–
mesenchymal transition; NK cell = natural killer T cell.
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decline in FVC and DLCO over 2 years were
independently associated with an increased
risk of mortality (29). A decline in the FVC
and the DLCO over 2 years was a better
predictor of mortality than the baseline
FVC and DLCO (29). In a long-term study
of the prognostic significance of pulmonary
function test changes, the strongest 1-year
predictor of future mortality in patients
with SSc-ILD was a composite endpoint
defined either by a decline from baseline in
FVC of >10% or a decline of 5% to 9% in
FVC with a decrease in DLCO of>15% (30).
Thus, short-term changes in measurements
of SSc-ILD progression appear to have
important implications regarding long-
term outcomes. The overlap between risk
factors for ILD progression and for
increased mortality is unsurprising.
Treatment of SSc-ILD is beyond the
scope of this review; however, several
landmark studies have indicated that some
treatments may be able to stabilize or slow
down disease progression and, therefore,
improve patient outcomes. All these trials
focused on patients with clinically
meaningful ILD, defined as a combination
of moderate to severe ILD on HRCT
and abnormal pulmonary physiology
with symptoms. SLS I showed that 12
months of treatment of SSc-ILD with
cyclophosphamide (CYC) improved FVC %
predicted by 2.53% versus placebo
(P, 0.03). A modest benefit was also
reported in TLC, dyspnea, skin thickening,
and health-related quality of life (31, 32).
SLS II was a 24-month study comparing
2-year treatment with mycophenolate
mofetil (MMF) with 1 year of treatment
with CYC followed by 1 year of placebo in
patients with SSc-ILD. The two treatment
approaches showed similar efficacy in terms
of FVC % predicted (mean improvement
of 2.19% and 2.88%, respectively) at
24 months. However, MMF treatment was
reported to be better tolerated (e.g., lower
rates of leucopenia and thrombocytopenia)
(33). The Fibrosing Alveolitis in
Scleroderma Trial was a randomized,
placebo-controlled study of low-dose
prednisolone and six-monthly doses of
intravenous CYC and oral azathioprine.
Compared with placebo, study intervention
showed a nonsignificant trend toward
improving FVC (treatment difference,
4.19%; P= 0.08) (34). Recently, nintedanib
became the first U.S. Food and Drug
Administration–approved treatment for
SSc-ILD; it is indicated for slowing the rate
of decline in pulmonary function in
patients with SSc-associated ILD on the
basis of the results of the phase III,
randomized, double-blind placebo-
controlled SENSCIS (Safety and Efficacy of
Nintedanib in Systemic Sclerosis) trial (35).
Primary endpoint analysis in the SENSCIS
trial showed that the adjusted annual rate of
A B C
D E F
Figure 2. (A–C) Limited disease (,20% extent) on high-resolution computed tomography (HRCT)
imaging in a 72-year-old female nonsmoker. HRCT images at the level of (A) the aortic arch show
no convincing interstitial lung disease (ILD), and (B and C) very limited subpleural ground-glass
opacification. (D–F) ILD of “indeterminate” extent on HRCT imaging in a 46-year-old female
nonsmoker with systemic sclerosis. (A–D) The upper zones show minor reticulation, (E) just below
the level of the right hemidiaphragm, and (F) the costophrenic recesses demonstrating reticulation,
ground-glass opacification, and traction bronchiectasis/bronchiolectasis. The morphologic
features are in keeping with a fibrotic nonspecific interstitial pneumonia pattern. Disease extent on
HRCT imaging with regard to the 20% threshold is difficult to gauge (i.e., “indeterminate” according
to the Goh staging); FVC in this patient was 60% predicted, thereby indicating “extensive” ILD.
Note the marked esophageal dilatation containing food residue.
A B
C D
Figure 3. High-resolution computed tomography images in a 58-year-old woman with systemic
sclerosis who never smoked; DLCO 32% predicted and FVC 76% predicted. Axial images at (A) the
level of the aortic arch, (B) the carina, and (C) the lower lobes demonstrate extensive disease (.20%
extent by visual estimation) and (D) coronal reconstruction. There is marked honeycombing,
particularly in the lower lobes, indicating a usual interstitial pneumonia pattern. The coronal image
shows striking lower zone preponderance of disease.
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decline in FVC was 52.4 ml/yr in
nintedanib-treated patients versus 93.3
ml/yr in placebo-treated patients
(difference, 41.0 ml/yr; 95% confidence
interval, 2.9–79.0 ml/yr; P= 0.04) over a
1-year period in the total study population.
Subgroups analyses reported that
nintedanib reduced the progression of ILD
irrespective of mycophenolate use at
baseline. Statistical testing did not indicate
heterogeneity in the treatment effect of
nintedanib between those who were or were
not receiving mycophenolate at baseline
(P= 0.45 for treatment-by-time-by-
subgroup interaction). The absolute effect
of nintedanib versus placebo in reducing
the rate of decline in FVC was numerically
lower in patients who were receiving
mycophenolate at baseline compared
with those who were not receiving
mycophenolate at baseline (26.3 ml/yr vs.
55.4 ml/yr). The relative treatment effect of
nintedanib was similar between these
subgroups (40% and 46%, respectively) and
consistent with that observed in the overall
population (44%). No other significant
clinical benefits were observed (36).
Blood Serum and BAL Fluid
Biomarkers
Blood serum or BAL fluid (BALF)
biomarkers may be of value in diagnosing
SSc-ILD and in prognostication. A number
of potential biomarkers have been identified,
which could be indicative of lung
involvement in patients with SSc (Tables 1
and E3) (27). Autoantibodies are the only
blood markers currently available in routine
clinical practice (Tables 1 and E3). The
presence of anti–Scl-70 antibodies and the
absence of anticentromere antibodies in
SSc indicate an increased likelihood of
progressive ILD (20, 22, 37). Associations
of these antibodies with major
histocompatibility complex II antigens
support the genetic basis of SSc-ILD (37).
A number of biomarkers are being
investigated in clinical research (Tables 1
and E3), although they are not currently
available for use in routine clinical practice,
with the exception of KL-6 (Krebs von den
Lungen-6), which is available but only in
Japan. Among biomarkers under clinical
investigation, high plasma levels of KL-6
appear to be predictive of lung involvement
and ILD progression in patients with SSc
(23, 38, 39), including in SLS-II. Serum
CCL18 (chemokine [C-C motif] ligand 18),
a macrophage 2–derived protein that is
chemotactic for a number of immune cells,
has also been shown to be a good
prognostic marker, even after adjustment
for baseline ILD severity (40, 41). Analysis
of serum CCL18 was able to differentiate
the impact of tocilizumab versus placebo in
SSc with early ILD on FVC% (14).
Serum levels of MMP7 (matrix
metalloproteinase-7) are higher in patients
with SSc-ILD versus SSc without ILD, and
combined measurements of KL-6 and
MMP7 have been suggested for identifying
patients at risk of developing clinically
significant ILD (27). Higher levels of
MMP12 (matrix metalloproteinase-12)
have been found in patients with SSc-ILD
versus those without lung involvement; in
the population with SSc-ILD, increased
MMP12 levels appear to be associated with
lower FVC (42). Data from two cohorts of
patients with SSc showed that high plasma
concentrations of CCL2 are predictive of
ILD progression and shorter survival (43).
Elevated acute-phase reactants, such as high
plasma C-reactive protein levels, have been
associated with an increased likelihood of
progressive early SSc-ILD (44). Also,
elevated serum IL-6 levels have been
reported to be predictive of early disease
progression (specifically, declines in DLCO
and FVC or death within 12 mo) in patients
with SSc-ILD (12). However, IL-6 would
provide only low specificity for diagnosing
SSc-ILD, because its levels are elevated in a
range of inflammatory diseases.
A proteome-wide analysis in SSc
identified CXCL4 (chemokine [C-X-C
motif] ligand 4) as the principal protein
secreted by plasmacytoid dendritic cells
(45). Plasmacytoid dendritic cells in the
BALF are associated with the severity of
disease on HRCT in SSc-ILD (46). Plasma
levels of CXCL4 correlate with the
occurrence of ILD in patients with SSc, and
higher levels of this biomarker are
associated with more rapid decline in DLCO
(45). Volkmann and colleagues found that
plasma CXCL4 levels were higher in
patients with SSc-ILD compared with
healthy control subjects in SLS II; however,
the levels did not correlate with severity of
ILD at baseline (47). Plasma CXCL4 levels
reduced with immunosuppressive therapy;
larger declines observed over the first 12
months of treatment were associated with
greater improvements in lung function over
the subsequent 12 months (47). Moreover,
levels of antibodies against CXCL3
(chemokine [C-X-C motif] ligand 4) and
CXCL4 have been reported to be increased
in patients with SSc-ILD versus healthy
control subjects but lower in patients with
deteriorating versus stable lung function
(48). Serum levels of chitinase-3–like
protein 1, also known as YKL-40, have been
shown to be higher in patients with SSc
with versus those without pulmonary
involvement (49). Levels of chitinase 1 have
been reported to be significantly higher in
patients with SSc-ILD than in patients with
SSc and no lung involvement; as well as
being a candidate biomarker, this enzyme
could be considered as a therapeutic target
(50).
Currently, BAL is not routinely
performed in patients with SSc-ILD; the
previously observed link between BALF
neutrophilia andmortality was subsequently
found to bemainly related to disease severity
(51, 52). However, BAL has been shown to
be useful in identifying clinically
unsuspected infections in a small minority
of patients with SSc-ILD. If not
appropriately treated, such infections have
the potential to be aggravated by
immunosuppressive therapy (53). In
routine clinical practice, BAL is not
considered to provide additional
A B C
Figure 4. Computed tomography imaging in a 52-year-old man, ex-smoker, with a DLCO of 22% and
FVC 56% predicted. Axial images at (A) the level of the arch, (B) the pulmonary venous confluence,
and (C) the costophrenic recesses show extensive (.20%) disease. There is predominant ground-
glass opacification with fine reticulation, no honeycombing, but severe traction bronchiectasis. The
computed tomography features are consistent with a fibrotic nonspecific interstitial pneumonia
pattern. Note also the marked esophageal dilatation.
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meaningful prognostic information;
however, this could change if biomarkers
independent of disease severity and without
an equivalent correlate in the peripheral
blood are identified. BALF inflammatory
cytokines have been described as potential
predictive biomarkers of SSc-ILD
deterioration; this, however, has so far only
been reported in small patient cohorts (54).
Furthermore, proteomic and gene
expression analysis of BALF is likely to
provide insights that are specific to SSc-ILD
pathogenesis that may not be possible in
the peripheral blood. Proteomic analysis of
BALF has also identified the differential
expression of a number of potential
biomarkers including C3a (complement
3 anaphylatoxin), APOAI (apolipoprotein
A-I), 14-3-3e, SPFA2 (pulmonary
surfactant–associated protein A2), and
S100A6 (S100 calcium-binding protein A6),
involved in fibrosis, innate immune
responses, and vascular damage (55).
Comparison with IPF
Respiratory clinicians are often more
familiar with IPF than SSc-ILD, IPF being
the prototypic ILD; IPF affects a greater
number of patients and has been researched
more extensively than SSc-ILD. Not
surprisingly, there is a larger literature and
clinical experience in IPF compared with
SSc-ILD; therefore, it is logical to explore the
similarities and differences between SSc-ILD
and IPF. A comparative summary is
provided in Tables E3 and E4.
Although ILD occurs in a large
proportion of patients with SSc, only some
will experience disease that worsens over
time (2). Spontaneous regression can occur,
albeit rarely, in SSc-ILD, and the disease
course is likely to be stabilized by treatment
with immunosuppressants or as part of
natural history of the disease—changing
from a declining trend to stability or, in a
small percentage of cases, improving over
time (13, 56). In contrast, all patients with
IPF have progressive fibrosis, albeit at
different rates (57), which never undergoes
spontaneous regression.
Immunological involvement appears
to differ between SSc-ILD and IPF (Tables
E3 and E4), although adaptive and innate
immune mechanisms are implicated in
both diseases. Most patients with SSc-ILD
are positive for autoantibodies (e.g., antinuclear
antibodies), whereas clinically relevant levels of
Table 1. Clinically Used Biomarkers and Biomarkers under Investigation in SSc-ILD
Mechanistic Pathway and Biomarker References
Clinically used biomarkers
Immune dysregulation or inflammation
Anti-centromere 20, 22, 37
Anti–Scl-70 22, 37
Nucleolar pattern on ANA (representing anti-Th/To, U3 RNP) 83
Biomarkers supported by significant clinical data
Epithelial cell injury or barrier dysfunction
CCL-18 40, 61
KL-6* 23, 38, 39
SP-D 84
Immune dysfunction or inflammation
IL-6/CRP 12, 41
Biomarkers under investigation
Epithelial cell injury or barrier dysfunction
APOAI 55
CC16 85
ET-1 86
Isoprostane 86
SP-A 87
sE-selectin 86
sVCAM-1 86
SPFA2 55
S100A6 55
TGF-b 86
VEGF 86
14-3-3e 55
Immune dysfunction or inflammation
Anti-CXCR4 48
Anti-CXCR3 48
CCL2 43
CRP 88
CXCL4 45
CXCL10 89
CX3CL1 90
C3a 55
IL-10 86
IL-15 86
IL-17† 65
IL-22† 65
IL-23 86
miR-155 19
Remodeling and fibrosis
Chitinase-1 50
CTGF 86
Circulating fibrocytes 88
GDF-15 88
MMP7 27
MMP12 42
MMP13 88
miR-21 19
miR-92A 91
miR-200c 88
PMN elastase 86
TIMP-1 86
TIMP-2 88
YKL-40 49
Definition of abbreviations: 14-3-3e= tyrosine 3-monooxygenase/tryptophan 5-monooxygenase
activation protein epsilon; ANA= antinuclear antibody; anti-Th/To=Th/To ribonucleoprotein antibody;
APOAI = apolipoprotein A-I; C3a= complement 3 anaphylatoxin; CC16= club cell secretory protein
16; CCL=chemokine (C-C motif) ligand; CRP=C-reactive protein; CTGF=connective tissue
growth factor; CX3CL1=chemokine (C-X3-C motif) ligand 1; CXCL=chemokine (C-X-C motif) ligand;
CXCR3=chemokine (C-X-C motif) receptor 3; ET-1=endothelin-1; GDF-15=growth differentiation
factor–15; KL-6=Krebs von den Lungen-6; miR=microRNA; MMP=matrix metalloproteinase;
PMN=polymorphonuclear; S100A6=S100 calcium-binding protein A6; Scl-70= topoisomerase 1;
sE-selectin= soluble E selectin; SP-A=surfactant protein A; SP-D=surfactant protein D;
SPFA2=pulmonary surfactant–associated protein A2; SSc-ILD=systemic sclerosis–associated
interstitial lung disease; sVCAM-1=soluble vascular cell adhesion molecule 1; TGF-b= transforming
growth factor-b; TIMP-1= tissue inhibitors of metalloproteinases-1; U3 RNP=fibrillarin; VEGF=vascular
endothelial growth factor; YKL-40=chitinase-3-like protein 1.
*Approved by Japan’s Health Insurance Program as a diagnostic marker for interstitial lung diseases in 1999.
†Circulating IL-producing T cells.
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autoantibodies are believed to be absent from
patients with IPF (13). A single study has
reported a link between anti-HSP70 antibodies
and poor survival in IPF, although currently
this is not considered in routine clinical
practice (58). The existence of specific
activation mechanisms for different
macrophage subpopulations has been
described in IPF, whereby M1 macrophages
(inducers include LPS, IFN-g, and
granulocyte–stimulating colony–stimulating
factor) and M2 macrophages (inducers include
IL-4, IL-10, IL-13, and TGF-b) are both
involved in the pathogenesis of the disease
(59). IL-41 T cells in the BALF are associated
with the severity of disease on HRCT imaging
in SSc-ILD (60). Levels of CCL18 are increased
in BALF and serum of patients with either IPF
or SSc-ILD. In both diseases, serum CCL18
has been linked to worse prognosis
independent of disease severity (40, 61), and
levels of serum CCL18 appear to decrease in
response to anti-IL6 therapy (14), with
stabilization in lung function.
A study of lung tissue showed increased
mast cell density in patients with IPF
compared with healthy control subjects,
whereas mast cell density was similar in
patients with SSc-ILD and healthy control
subjects (62). Regarding adaptive
immunity, numbers of CD41 CD251
regulatory T cells in the lungs appear to
be increased in SSc-ILD but not in IPF
(63, 64). Also, increased numbers of IL-
22–producing T-helper cells have been
observed in SSc-ILD but not in IPF (65, 66).
Consistent with these findings, individuals
with SSc-ILD, but not those with IPF,
benefit from CYC treatment (13). There is,
therefore, good evidence to suggest that
adaptive immune mechanisms play a
reduced role in IPF compared with
SSc-ILD. In fact, few patients with
IPF are likely to respond to any
immunosuppressant therapy, whereas
most patients with SSc-ILD respond to
such treatment. Further understanding of
the phenotypes, activation mechanisms,
and roles of macrophages in lung fibrosis,
both in IPF and SSc-ILD, may help in the
development of therapeutic targets.
Some of the pathological pathways
involved in fibrogenesis in IPF are similar to
those in SSc-ILD. The initial trigger of
fibrosis in both diseases appears to be
epithelial and/or endothelial cell injury (13).
The associated cell death has several effects,
including the activation of TGF-b, which
then triggers immune responses and causes
fibroblast activation, proliferation, and
differentiation into myofibroblasts. These
processes culminate in the excess
deposition of ECM (11).
On histopathologic analysis, patients
with SSc-ILD usually exhibit fibrotic (rarely
cellular) nonspecific interstitial pneumonia
(NSIP; Figure 5) (67), whereas usual
interstitial pneumonia (UIP) may be
observed only in a minority of patients with
SSc-ILD. In contrast, UIP is the defining
morphological pattern in patients with IPF
(68). Patients with SSc-ILD and a UIP
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Figure 5. Histopathology of systemic sclerosis–associated interstitial lung disease (SSc-ILD) and idiopathic pulmonary fibrosis (13, 68). (A) SSc-ILD.
(Ai) Nonspecific interstitial pneumonia; note the diffuse alveolar septal thickening throughout the lobule with lack of peripheral accentuation in the
area of an interlobular septum on the left. (Aii) Usual interstitial pneumonia; note the peripheral involvement of a pulmonary lobule sparing the
centrilobular area containing the bronchovascular bundle. Arrows indicate fibroblastic foci. (Aiii) Pulmonary arterial hypertension; note the hypertensive
arterial changes with prominent intimal fibrosis. Arrow indicates separation of the media and intima by the internal elastic lamina. (Aiv) Pleural fibrosis;
its presence supports the diagnosis of SSc-ILD in the appropriate clinical setting. Hematoxylin and eosin (H&E)-stained sections are shown in Ai, Aii,
and Aiv; Verhoeff–van Gieson–stained sections in Aiii. Original magnification 340 in i and ii; 3200 in iii; 3100 in iv. (B) Usual interstitial pneumonia.
(Bi) At low magnification, the diagnostic key is the abrupt alternating of scarred and normal lung (patchwork pattern: scar-normal-scar-normal). In
the scarred areas, the alveolar architecture is obliterated. (Bii) The fibrosis frequently prevails at the periphery of the lobule in the subpleural paraseptal
regions (arrows), with relative sparing of the centrolobule. This is a useful diagnostic clue, particularly in early cases like this (H&E 20). (Biii) Honeycomb
consists of enlarged airspaces lined by bronchiolar epithelium, frequently filled by mucus and surrounded by dense scars. Note the architectural
distortion and the abrupt transition with residual normal lung seen in the right upper corner. (Biv) A fibroblastic focus consisting of a dome-shaped
proliferation of myofibroblasts immersed in a myxoid matrix. Fibroblastic foci can be covered by bronchiolar epithelium, as here, or by hyperplasic
pneumocytes. H&E-stained sections are shown in Bi–Biv. (A) Reprinted from Arthritis & Rheumatology, Vol. 66, Herzog EL, et al., Review: Interstitial
Lung Disease Associated With Systemic Sclerosis and Idiopathic Pulmonary Fibrosis: How Similar and Distinct? 1967–1978, Copyright (2014), by
permission from John Wiley & Sons. (B) Reprinted from Respiratory Medicine, Vol. 104, Cavazza A, et al., The role of histology in idiopathic pulmonary
fibrosis: An update, S11–S22, Copyright (2010), by permission from Elsevier.
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pattern have a better prognosis than
patients with IPF; moreover, patients with
SSc and a UIP pattern do not appear to
have a significantly worse survival than
patients with SSc and NSIP (69, 70).
Although the reasons for this are unclear,
UIP in patients with a connective tissue
disease is characterized by higher numbers
of lymphoid follicles, smaller honeycomb
cysts, and fewer fibroblastic foci compared
with UIP in IPF (71).
Genetic variants associated with SSc-
ILD and IPF do not appear to overlap. The
association with the MUC5B (mucin 5B)
promoter variant rs35705950, observed in
sporadic IPF and familial idiopathic
interstitial pneumonias (IIPs), is one
notable example that is absent in SSc-ILD
(72, 73). MUC5B expression is increased
in the small airways and honeycomb cysts
in UIP/IPF but similar to control subjects
in the small airways of patients with SSc
with an NSIP pattern (74). More generally,
the genetic susceptibility loci identified in
IIPs were not observed in a large North
American cohort of patients with SSc-ILD
(75). It is possible that the underlying
genetics of ILDs are related to the different
histopathological patterns. For example,
rheumatoid arthritis–associated ILD with
a UIP pattern is associated with the
MUC5B promoter variant rs35705950
(76); however, the same variant has
also been associated with idiopathic NSIP
(77). Further studies are needed to
characterize the link between genetic
characteristics and ILD patterns. A
number of HLA alleles have been
associated with SSc-ILD, as discussed
previously. Although associations
between HLA alleles and IIP have been
reported (78, 79), specific HLA allele
associations do not overlap between SSc-
ILD and IPF. For instance, HLA
DRB1*1501, observed to be associated
with IPF (78), has been reported as
protective against SSc (80).
Epigenetic changes may underpin
bronchiolar remodeling and the associated
formation of enlarged bronchiolized
airspaces (i.e., honeycombing, which occurs
to differing extents in IPF and SSc-ILD).
Chilosi and colleagues were the first to
highlight the importance of the
bronchioloalveolar junction and to report
overexpression ofmarkers of theWnt pathway
(e.g., b-catenin and MMP7) in IPF but not in
NSIP (81). Differences between SSc-ILD and
IPF are likely in specific miRNA profiles as
well as in other epigenetic parameters; further
studies are needed to characterize these
differences and their relevance.
Despite treatment not being the focus
of this review, we briefly mention some
important differences and similarities in
terms of treatment of SSc-ILD and IPF as
highlighted by key clinical trials. The
antifibrotic agents nintedanib and
pirfenidone have shown benefit and are
approved as treatments in IPF. In SSc-ILD,
nintedanib has been granted U.S. Food and
Drug Administration approval to slow the
rate of decline in pulmonary function in
patients with SSc-ILD on the basis of the
results of the phase III SENSCIS trial,
similar to its effect in patients with IPF.
Furthermore, and in line with the known
safety profile of nintedanib in patients with
IPF, diarrhea was the most common
adverse event (AE); all reported AEs were
at worst mild or moderate in severity, as
reported in 49.5% and 45.0% of patients,
respectively (36). The phase II LOTUSS
(Safety and Tolerability of Pirfenidone in
Participants with SSc-ILD) trial showed
that pirfenidone administered either as
monotherapy or in combination with
MMF had an acceptable tolerability profile
in patients with SSc-ILD. The most common
AEs were nausea, headache, and fatigue,
which is consistent with its tolerability
profile in patients with IPF (82). SLS III
(NCT03221257), for which recruitment was
ongoing at the time of writing, was designed
to compare pirfenidone plus MMF with
MMF alone in SSc-ILD. The results of this
study, due in May 2021, may provide further
data regarding the similarities and
differences between treatment response in
SSc-ILD and IPF.
Conclusions
ILD is a common complication of
SSc and a significant cause of morbidity
and mortality. Differentiation from
IPF is particularly important, because
IPF is the most common fibrosing
ILD. This is usually straightforward in
the context of the classic extrapulmonary
SSc manifestations but can be more
difficult in patients with SSc sine
scleroderma. Knowledge of SSc-ILD
is important in our community to
ensure that affected patients are
managed optimally. Greater extent
of lung fibrosis on HRCT, lower FVC,
and early lung function decline are
predictors of early mortality. Familiarity
with key clinical features (including
established risk factors of progressive
lung disease) may prove useful in
raising our alertness to the possibility of
SSc-ILD in relevant patients. Perhaps
most importantly, high awareness of the
disease and its characteristics will be
needed to realize the potential of new
treatment options. n
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